292 results on '"LAWS, ELIZABETH"'
Search Results
2. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
3. Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
4. Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
5. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
6. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
7. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
8. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
9. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
10. Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study
11. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study
12. Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy
13. Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroid (VOYAGE)
14. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
15. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
16. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
17. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
18. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
19. Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
20. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
21. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
22. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
23. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
24. DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS.
25. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
26. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
27. Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study
28. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL
29. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE NOTUS TRIAL
30. IN THE PHASE 3 BOREAS TRIAL, DUPILUMAB REDUCED FENO LEVELS OVER TIME IN PATIENTS WITH MODERATE OR SEVERE SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH TYPE 2 INFLAMMATION
31. IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL
32. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED BOREAS AND NOTUS RESULTS
33. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA
34. A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic Duodenitis
35. Baseline Demographics And Disease Characteristics Of Pediatric Patients With Eosinophilic Esophagitis (EoE) From The Randomised, Placebo-Controlled, Phase 3 EoE KIDS Study
36. Dupilumab Normalized The Expression Of Genes Dysregulated In Eosinophilic Esophagitis (EoE) In Esophageal Biopsies From A Clinical Trial Of Children Aged 1–11 Years
37. Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS Trial
38. 507 - Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU
39. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma
40. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study
41. Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics
42. Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
43. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
44. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study
45. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
46. S1876 An Adaptive Phase 2/3 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults and Adolescents With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
47. S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
48. S461 Dupilumab Efficacy in Eosinophilic Esophagitis Persists for Histologic, Symptomatic, and Endoscopic Outcomes Regardless of Concomitant High-Dose Proton Pump Inhibitor Use
49. EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
50. Dupilumab in Asia-Pacific patients with persistent asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.